Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
FLT3 and leukemia are reported together in 36 articles.
Gene
FLT3
- HGNC
- HGNC:3765
42articles
42mentions
1variants with confirmed gene link
Most co-reported phenotypes (articles)
Reported variants (articles · ClinVar status)
Phenotype
Leukemia
652articles
652mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
36 records shown · first 60The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutations.
PMID 41437149 | DOI 10.1038/s41409-025-02765-1 · Bone marrow transplantation · 2026 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “Among patients with cytogenetically normal AML, the triple-positive mutation group (DNMT3A, NPM1, and FLT3-ITD) was the most frequent (n = 340, 29%), while DNMT3A co-occurrence with either FLT3 or NPM1 mutations alone was less common (4% and 9%, respectively).” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutations.” | 0.93 | phenotype_alias_lexicon_v2 |
| gene | DNMT3A | “The impact of DNMT3A mutation on survival of AML patients receiving allotransplant in first remission depends on the karyotype and co-occurring mutations.” | 0.98 | hgnc_dict_v1 |
| gene | ELN | “Mutations in the DNMT3A gene are not yet classified as a distinct prognostic group in the latest European Leukemia Net (ELN) 2022 genetic risk classification of AML.” | 0.98 | hgnc_dict_v1 |
Biomarkers and advances in AML-MRC: from bench to bedside.
PMID 41711916 | PMCID PMC12920406 | DOI 10.1007/s00277-026-06805-8 · Annals of hematology · 2026 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “Additionally, we discuss emerging therapies, including CPX-351, hypomethylating agents (HMAs), targeted inhibitors (e.g., FLT3 and IDH1/2 inhibitors), and immunotherapies, while addressing the challenges of treatment resistance and relapse.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) represents a high-risk subtype of AML, characterized by poor prognosis and limited therapeutic options.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | TP53 | “This review provides a comprehensive overview of the pathogenesis, key biomarkers, and diagnostic innovations in AML-MRC, highlighting the role of genetic mutations (e.g., TP53, RUNX1, and splicing factors), cytogenetic abnormalities, and immune microenvironment alterations.” | 0.98 | hgnc_dict_v1 |
| gene | RUNX1 | “This review provides a comprehensive overview of the pathogenesis, key biomarkers, and diagnostic innovations in AML-MRC, highlighting the role of genetic mutations (e.g., TP53, RUNX1, and splicing factors), cytogenetic abnormalities, and immune microenvironment alterations.” | 0.98 | hgnc_dict_v1 |
Mechanistic Insights into the Therapeutic Role of Curcumin in Leukemia: Molecular Targets and Clinical Implications.
PMID 41036753 | DOI 10.2174/0113892010367533250923105438 · Current pharmaceutical biotechnology · 2025 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “It downregulates oncogenes, such as FLT3, Akt, ROS, and NF-κB, while protecting normal cells through upregulation of NRF-2, which enhances antioxidant production.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Mechanistic Insights into the Therapeutic Role of Curcumin in Leukemia: Molecular Targets and Clinical Implications.” | 0.98 | phenotype_alias_lexicon_v2 |
Application of Newly Customized Myeloid NGS Panel in the Diagnosis of Myeloid Malignancies.
PMID 38204493 | PMCID PMC10777859 | DOI 10.2147/IJGM.S437327 · International journal of general medicine · 2024 · 13 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “This panel was designed to sequence the complete genome of CALR, IDH1, IDH2, JAK2, FLT3, NPM1, MPL, TET2, SF3B1, TP53, and MLL.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “PURPOSE: Genetic mutations are major factors in the diagnosis and prognosis of leukemia, and it is difficult to assess these variants using single-gene analysis.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CALR | “This panel was designed to sequence the complete genome of CALR, IDH1, IDH2, JAK2, FLT3, NPM1, MPL, TET2, SF3B1, TP53, and MLL.” | 0.98 | hgnc_dict_v1 |
| gene | IDH1 | “This panel was designed to sequence the complete genome of CALR, IDH1, IDH2, JAK2, FLT3, NPM1, MPL, TET2, SF3B1, TP53, and MLL.” | 0.98 | hgnc_dict_v1 |
Exploring the interplay between microRNA expression and DNA mutation analysis in AML patients.
PMID 38831894 | PMCID PMC11145380 | DOI 10.1016/j.sjbs.2024.104027 · Saudi journal of biological sciences · 2024 · 11 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “The molecular analysis results unveiled mutations in specific genes (FLT3, KIT, PTPN11, BCR, DNMT3A, and NRAS) targeted by nine microRNAs.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Exploring the interplay between microRNA expression and DNA mutation analysis in AML patients.” | 0.93 | phenotype_alias_lexicon_v2 |
| gene | CD99 | “Cell surface protein expression analysis revealed upregulation of CD45, CD99, CD34, HLA-DR, CD38, CD13, CD33, MPO, CD15 and CD117 in AML patients.” | 0.98 | hgnc_dict_v1 |
| gene | CD34 | “Cell surface protein expression analysis revealed upregulation of CD45, CD99, CD34, HLA-DR, CD38, CD13, CD33, MPO, CD15 and CD117 in AML patients.” | 0.98 | hgnc_dict_v1 |
Discovery and Anticancer Screening of Novel Oxindole-Based Derivative Bearing Pyridyl Group as Potent and Selective Dual FLT3/CDK2 Kinase Inhibitor.
PMID 38794229 | PMCID PMC11124822 | DOI 10.3390/ph17050659 · Pharmaceuticals (Basel, Switzerland) · 2024 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “Discovery and Anticancer Screening of Novel Oxindole-Based Derivative Bearing Pyridyl Group as Potent and Selective Dual FLT3/CDK2 Kinase Inhibitor.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Among these kinases, FLT3 is a member of class III receptor tyrosine kinase family which is abundantly expressed in individuals with acute leukemia.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CDK2 | “Discovery and Anticancer Screening of Novel Oxindole-Based Derivative Bearing Pyridyl Group as Potent and Selective Dual FLT3/CDK2 Kinase Inhibitor.” | 0.98 | hgnc_dict_v1 |
| phenotype | colorectal cancer | “This leads to the discovery of a potent antiproliferative compound, namely 5l, with an average GI50 value against leukemia and colon cancer subpanels equalling 3.39 and 5.97 µM, respectively.” | 0.93 | phenotype_alias_lexicon_v2 |
Landscape of FLT3 Variations Associated with Structural and Functional Impact on Acute Myeloid Leukemia: A Computational Study.
PMID 38542393 | PMCID PMC10970727 | DOI 10.3390/ijms25063419 · International journal of molecular sciences · 2024 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “Landscape of FLT3 Variations Associated with Structural and Functional Impact on Acute Myeloid Leukemia: A Computational Study.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Landscape of FLT3 Variations Associated with Structural and Functional Impact on Acute Myeloid Leukemia: A Computational Study.” | 0.98 | phenotype_alias_lexicon_v2 |
| variant | I863F | “A computational structural analysis of the deleterious variants of FLT3 revealed I863F mutants as destabilizers of the protein structure, possibly leading to functional changes.” | 0.82 | literature_variant_regex_v2 |
Decoding the anti-cancer potential of Pexidartinib (PLX3397), a Fms-like tyrosine kinase 3 inhibitor, using next-generation knowledge discovery methods.
PMID 39132250 | PMCID PMC11309106 | DOI 10.6026/973206300200460 · Bioinformation · 2024 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “The FMS-like tyrosine kinase 3 (FLT3), a receptor tyrosine kinase, plays a pivotal role in regulating cell survival, proliferation, and differentiation within the hematopoietic system.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Acute Myeloid Leukemia (AML) is a complex hematologic malignancy characterized by the rapid proliferation of abnormal myeloid precursor cells.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | CSF1R | “PLX3397 exerts its inhibitory effects by targeting CSF1R and KIT, leading to the disruption of receptor tyrosine kinase signalling cascades, suppression of leukemic cell growth, and induction of apoptosis.” | 0.98 | hgnc_dict_v1 |
Identifying novel therapeutic inhibitors to target FMS-like tyrosine kinase-3 (FLT3) against acute myeloid leukemia: a molecular docking, molecular dynamics, and DFT study.
PMID 36995071 | DOI 10.1080/07391102.2023.2192798 · Journal of biomolecular structure & dynamics · 2024 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “Identifying novel therapeutic inhibitors to target FMS-like tyrosine kinase-3 (FLT3) against acute myeloid leukemia: a molecular docking, molecular dynamics, and DFT study.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Identifying novel therapeutic inhibitors to target FMS-like tyrosine kinase-3 (FLT3) against acute myeloid leukemia: a molecular docking, molecular dynamics, and DFT study.” | 0.98 | phenotype_alias_lexicon_v2 |
Discovery of oxindole-based FLT3 inhibitors as a promising therapeutic lead for acute myeloid leukemia carrying the oncogenic ITD mutation.
PMID 36403191 | DOI 10.1002/ardp.202200407 · Archiv der Pharmazie · 2023 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “Discovery of oxindole-based FLT3 inhibitors as a promising therapeutic lead for acute myeloid leukemia carrying the oncogenic ITD mutation.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Discovery of oxindole-based FLT3 inhibitors as a promising therapeutic lead for acute myeloid leukemia carrying the oncogenic ITD mutation.” | 0.98 | phenotype_alias_lexicon_v2 |
Beta Elemene induces cytotoxic effects in FLT3 ITD-mutated acute myeloid leukemia by modulating apoptosis.
PMID 37140277 | DOI 10.26355/eurrev_202304_32098 · European review for medical and pharmacological sciences · 2023 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “Beta Elemene induces cytotoxic effects in FLT3 ITD-mutated acute myeloid leukemia by modulating apoptosis.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Beta Elemene induces cytotoxic effects in FLT3 ITD-mutated acute myeloid leukemia by modulating apoptosis.” | 0.98 | phenotype_alias_lexicon_v2 |
Favorable outcome of PML-RARα short isoform and FLT3-ITD mutation in a patient with several adverse prognostic markers: A case report.
PMID 37426684 | PMCID PMC10323718 | DOI 10.1002/ccr3.7637 · Clinical case reports · 2023 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “The use of FLT3 inhibitor in APL induction management is implicated to prevent differentiation syndrome and coagulopathy experienced in in patients with FLT3-ITD.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “ABSTRACT: FLT3-ITD mutations are the most common activating mutations in FLT3 gene, occurring in about 12 to 38% of acute promyelocytic leukemia cases, and are mainly associated with high white blood cell counts and poor clinical outcomes.” | 0.98 | phenotype_alias_lexicon_v2 |
Combination of an Oxindole Derivative with (-)-β-Elemene Alters Cell Death Pathways in FLT3/ITD+ Acute Myeloid Leukemia Cells.
PMID 37446914 | PMCID PMC10343312 | DOI 10.3390/molecules28135253 · Molecules (Basel, Switzerland) · 2023 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “Combination of an Oxindole Derivative with (-)-β-Elemene Alters Cell Death Pathways in FLT3/ITD+ Acute Myeloid Leukemia Cells.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Combination of an Oxindole Derivative with (-)-β-Elemene Alters Cell Death Pathways in FLT3/ITD+ Acute Myeloid Leukemia Cells.” | 0.98 | phenotype_alias_lexicon_v2 |
FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review.
PMID 37717880 | DOI 10.1016/j.critrevonc.2023.104139 · Critical reviews in oncology/hematology · 2023 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “FLT3 inhibitors and novel therapeutic strategies to reverse AML resistance: An updated comprehensive review.” | 0.93 | phenotype_alias_lexicon_v2 |
FMS-like tyrosine kinase-3 (FLT3) inhibitors with better binding affinity and ADMET properties than sorafenib and gilteritinib against acute myeloid leukemia: in silico studies.
PMID 34486940 | DOI 10.1080/07391102.2021.1969286 · Journal of biomolecular structure & dynamics · 2022 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “FMS-like tyrosine kinase-3 (FLT3) inhibitors with better binding affinity and ADMET properties than sorafenib and gilteritinib against acute myeloid leukemia: in silico studies.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “FMS-like tyrosine kinase-3 (FLT3) inhibitors with better binding affinity and ADMET properties than sorafenib and gilteritinib against acute myeloid leukemia: in silico studies.” | 0.98 | phenotype_alias_lexicon_v2 |
Gene Expression Analysis of Pediatric Acute Myeloid Leukemia Identified a Hyperactive ASXL1/BAP1 Axis Linked with Poor Prognosis and over Expressed Epigenetic Modifiers.
PMID 33764257 | DOI 10.1080/08880018.2021.1901808 · Pediatric hematology and oncology · 2021 · 9 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “Age, gender, hematological data or molecular risk factors (FLT3 mutation/molecular fusion) exposed no significant differences across these two distinct ASXL1 expression groups (P > 0.05).” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Gene Expression Analysis of Pediatric Acute Myeloid Leukemia Identified a Hyperactive ASXL1/BAP1 Axis Linked with Poor Prognosis and over Expressed Epigenetic Modifiers.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | ASXL1 | “Gene Expression Analysis of Pediatric Acute Myeloid Leukemia Identified a Hyperactive ASXL1/BAP1 Axis Linked with Poor Prognosis and over Expressed Epigenetic Modifiers.” | 0.98 | hgnc_dict_v1 |
| gene | BAP1 | “Gene Expression Analysis of Pediatric Acute Myeloid Leukemia Identified a Hyperactive ASXL1/BAP1 Axis Linked with Poor Prognosis and over Expressed Epigenetic Modifiers.” | 0.98 | hgnc_dict_v1 |
RUNX1 mutation and elevated FLT3 gene expression cooperates to induce inferior prognosis in cytogenetically normal acute myeloid leukemia patients.
PMID 34466057 | PMCID PMC8381075 | DOI 10.1016/j.sjbs.2021.07.012 · Saudi journal of biological sciences · 2021 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “RUNX1 mutation and elevated FLT3 gene expression cooperates to induce inferior prognosis in cytogenetically normal acute myeloid leukemia patients.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “RUNX1 mutation and elevated FLT3 gene expression cooperates to induce inferior prognosis in cytogenetically normal acute myeloid leukemia patients.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | RUNX1 | “RUNX1 mutation and elevated FLT3 gene expression cooperates to induce inferior prognosis in cytogenetically normal acute myeloid leukemia patients.” | 0.98 | hgnc_dict_v1 |
| variant | K83E | “RESULTS: Eight patients (25%) carried RUNX1 mutation (K83E) while three patients (9.37%) were found to have internal tandem duplications in FLT3 gene.” | 0.82 | literature_variant_regex_v2 |
The Structural Effect of FLT3 Mutations at 835th Position and Their Interaction with Acute Myeloid Leukemia Inhibitors: In Silico Approach.
PMID 34299222 | PMCID PMC8303888 | DOI 10.3390/ijms22147602 · International journal of molecular sciences · 2021 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “The Structural Effect of FLT3 Mutations at 835th Position and Their Interaction with Acute Myeloid Leukemia Inhibitors: In Silico Approach.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “The Structural Effect of FLT3 Mutations at 835th Position and Their Interaction with Acute Myeloid Leukemia Inhibitors: In Silico Approach.” | 0.98 | phenotype_alias_lexicon_v2 |
| variant | D835A | “The most common point mutation in FLT3 occurs at the 835th residue (D835A/E/F/G/H/I/N/V/Y), in the activation loop region.” | 0.82 | literature_variant_regex_v2 |
An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1.
PMID 31935293 | PMCID PMC6960481 | DOI 10.1182/bloodadvances.2019000168 · Blood advances · 2020 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “A number of concurrent and cooperating mutations clearly play a role in modulating the proliferative potential of cells, including mutations in KIT, FLT3, and possibly JAK2.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1-RUNX1T1.” | 0.93 | phenotype_alias_lexicon_v2 |
| gene | JAK2 | “A number of concurrent and cooperating mutations clearly play a role in modulating the proliferative potential of cells, including mutations in KIT, FLT3, and possibly JAK2.” | 0.98 | hgnc_dict_v1 |
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
PMID 32241850 | PMCID PMC7271578 | DOI 10.3324/haematol.2019.243410 · Haematologica · 2020 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “The FMS-like tyrosine kinase 3 (FLT3) gene is mutated in 25-30% of patients with acute myeloid leukemia (AML).” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.” | 0.98 | phenotype_alias_lexicon_v2 |
Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study.
PMID 31707416 | PMCID PMC6901761 | DOI 10.15537/smj.2019.11.24584 · Saudi medical journal · 2019 · 4 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “However, complex cytogenetic was associated with the lowest OS rate; fms-like tyrosine kinase 3 (FLT3)-internal tandem duplication was independently correlated with low OS rate.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | NPM1 | “The most frequent molecular abnormalities were promyelocytic leukemia/retinoic acid receptor alpha (PML-RARA) (16.1%) and Nucleophosmin 1 (NPM1) (11.5%).” | 0.98 | hgnc_dict_v1 |
| population | Saudi Arabia, Jeddah | “OBJECTIVES: To determined the 5-year overall survival (OS) rates for adult patients with acute myeloid leukemia (AML) patients at King Abdulaziz Medical City, Jeddah, Saudi Arabia, based on cytogenetic and molecular abnormalities. The remaining 87 adult patients with de novo AML were enrolled in this study.” | 0.95 | saudi_context_rules_v1 |
Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.
PMID 31122828 | DOI 10.1016/j.clml.2019.04.004 · Clinical lymphoma, myeloma & leukemia · 2019 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “BACKGROUND: Patients diagnosed with acute myeloid leukemia (AML) with Fms-like tyrosine kinase 3 (FLT3) mutations have a very poor prognosis, despite use of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and salvage treatments.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.” | 0.98 | phenotype_alias_lexicon_v2 |
The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report.
PMID 31672129 | PMCID PMC6822434 | DOI 10.1186/s12884-019-2522-1 · BMC pregnancy and childbirth · 2019 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “CASE PRESENTATION: A 28-years-old woman in the 26th week of gestation diagnosed with FLT3/ITD-mutated AML, complete remission was induced by Daunorubicin and Cytarabine, and subsequently with 5-azacytidine (75 mg/m2 daily for 7 days) with no fetal hematological or toxicity issues.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report.” | 0.98 | phenotype_alias_lexicon_v2 |
Targeting FLT3 Mutations in Acute Myeloid Leukemia.
PMID 29316714 | PMCID PMC5789277 | DOI 10.3390/cells7010004 · Cells · 2018 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “Targeting FLT3 Mutations in Acute Myeloid Leukemia.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Targeting FLT3 Mutations in Acute Myeloid Leukemia.” | 0.98 | phenotype_alias_lexicon_v2 |
Detection of FLT3/TKD and IDH1 Mutations in Pakistani Acute Myeloid Leukemia Patients by Denaturing HPLC.
PMID 27735988 | DOI 10.1002/jcb.25761 · Journal of cellular biochemistry · 2017 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “Detection of FLT3/TKD and IDH1 Mutations in Pakistani Acute Myeloid Leukemia Patients by Denaturing HPLC.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Detection of FLT3/TKD and IDH1 Mutations in Pakistani Acute Myeloid Leukemia Patients by Denaturing HPLC.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | IDH1 | “Detection of FLT3/TKD and IDH1 Mutations in Pakistani Acute Myeloid Leukemia Patients by Denaturing HPLC.” | 0.98 | hgnc_dict_v1 |
Cytogenetic Profile and FLT3 Gene Mutations of Childhood Acute Lymphoblastic Leukemia.
PMID 28811744 | PMCID PMC5528943 | DOI 10.1177/1179554917721710 · Clinical Medicine Insights. Oncology · 2017 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “Cytogenetic Profile and FLT3 Gene Mutations of Childhood Acute Lymphoblastic Leukemia.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Cytogenetic Profile and FLT3 Gene Mutations of Childhood Acute Lymphoblastic Leukemia.” | 0.98 | phenotype_alias_lexicon_v2 |
| population | Saudi Arabia | “AIMS: There are insufficient data of cytogenetic profiles in Saudi Arabian patients with childhood ALL leukemia. We have examined a cohort of 110 cases of ALL to determine the cytogenetic profiles and prevalence of FLT3 mutations and analysis of the more frequently observed abnormalities and its correlations to other biologic factors and patient outcomes and to compare our results with previously published results.” | 0.95 | saudi_context_rules_v1 |
Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
PMID 28387928 | DOI 10.1002/cncr.30680 · Cancer · 2017 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “BACKGROUND: Sorafenib has shown encouraging results in patients with Fms-like tyrosine kinase 3 (FLT3)-positive acute myeloid leukemia.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.” | 0.98 | phenotype_alias_lexicon_v2 |
Novel anticancer compound [trifluoromethyl-substituted pyrazole N-nucleoside] inhibits FLT3 activity to induce differentiation in acute myeloid leukemia cells.
PMID 26916980 | DOI 10.1016/j.canlet.2016.02.028 · Cancer letters · 2016 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “Novel anticancer compound [trifluoromethyl-substituted pyrazole N-nucleoside] inhibits FLT3 activity to induce differentiation in acute myeloid leukemia cells.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Novel anticancer compound [trifluoromethyl-substituted pyrazole N-nucleoside] inhibits FLT3 activity to induce differentiation in acute myeloid leukemia cells.” | 0.98 | phenotype_alias_lexicon_v2 |
Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis.
PMID 27315441 | PMCID PMC5030151 | DOI 10.1002/cncr.30140 · Cancer · 2016 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia?” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia?” | 0.98 | phenotype_alias_lexicon_v2 |
FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
PMID 27450971 | DOI 10.1016/j.clml.2016.06.002 · Clinical lymphoma, myeloma & leukemia · 2016 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “FLT3 Inhibitors for Treating Acute Myeloid Leukemia.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “FLT3 Inhibitors for Treating Acute Myeloid Leukemia.” | 0.98 | phenotype_alias_lexicon_v2 |
Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients.
PMID 24696688 | PMCID PMC3950551 | DOI 10.1155/2014/141360 · Advances in hematology · 2014 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients.” | 0.98 | phenotype_alias_lexicon_v2 |
| population | Saudi Arabia | “Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients. We analyzed the frequency of FLT3 mutations (ITD and D835) in patients with AML at diagnosis; no sufficient data currently exist regarding FLT3 mutations in Saudi AML patients. The frequency of FLT3 mutations in our study (18.56%) was lower than many of the reported studies, FLT3-ITD mutations were observed in 14.4%, and FLT3-TKD in 4.1%, of 97 newly diagnosed AML patients (82 adult and 15 pediatric).” | 0.95 | saudi_context_rules_v1 |
FLT3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical Significance.
PMID 24959335 | PMCID PMC4063605 | DOI 10.4084/MJHID.2014.038 · Mediterranean journal of hematology and infectious diseases · 2014 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “FLT3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical Significance.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “FLT3 Internal Tandem Duplication and D835 Mutations in Patients with Acute Lymphoblastic Leukemia and its Clinical Significance.” | 0.98 | phenotype_alias_lexicon_v2 |
| population | Saudi Arabia | “Currently, there is no published data on FLT3 mutations in Saudi acute lymphoblastic leukemia (ALL) patients. In this retrospective study, we have examined a cohort of 77 ALL patients to determine the prevalence of FLT3 mutations and the possible prognostic relevance of these mutations in ALL patients. Our findings suggest that FLT3 mutations are not common in Saudi ALL and do not affect clinical outcome.” | 0.95 | saudi_context_rules_v1 |
Novel t(7;10)(p22;p24) along with NPM1 mutation in patient with relapsed acute myeloid leukemia.
PMID 24413869 | PMCID PMC6074915 | DOI 10.5144/0256-4947.2013.619 · Annals of Saudi medicine · 2013 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “Cytogenetic and molecular analyses were performed in this case at the time of relapse to find out the chromosomal abnormalities and genetic abnormalities like FMS-like tyrosine kinase (FLT3) and nucleophosmin (NPM1) mutation.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Novel t(7;10)(p22;p24) along with NPM1 mutation in patient with relapsed acute myeloid leukemia.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | NPM1 | “Novel t(7;10)(p22;p24) along with NPM1 mutation in patient with relapsed acute myeloid leukemia.” | 0.98 | hgnc_dict_v1 |
Detection of nucleophosmin and FMS-like tyrosine kinase-3 gene mutations in acute myeloid leukemia.
PMID 21245599 | PMCID PMC3101725 | DOI 10.4103/0256-4947.75778 · Annals of Saudi medicine · 2011 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “We sought to detect the nucleophosmin and FMS-like tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutations among Iranian patients with AML and to assess the relationship between these mutations and the subtypes of the disease.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Detection of nucleophosmin and FMS-like tyrosine kinase-3 gene mutations in acute myeloid leukemia.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | NPM1 | “CONCLUSION: Our data showed a high frequency of NPM1 mutations in the monocytic subtypes of AML, as well as a high degree of association between the occurrence of NPM1 and FLT3/ITD mutations.” | 0.98 | hgnc_dict_v1 |
The challenge of risk stratification in acute myeloid leukemia with normal karyotype.
PMID 20063545 | DOI 10.1016/s1658-3876(08)50023-9 · Hematology/oncology and stem cell therapy · 2008 · 7 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “Emerging evidence reveals that at the submicroscopic level, AML with normal cytogenetics may carry poor prognostic genetic lesions or "molecular signatures" as is the case with FLT3 mutations and overexpression of BAALC, ERG or MN1, or may have aberrations that predict better risk as is the case with isolated NPM1 or CEBPA mutations.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “The challenge of risk stratification in acute myeloid leukemia with normal karyotype.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | BAALC | “Emerging evidence reveals that at the submicroscopic level, AML with normal cytogenetics may carry poor prognostic genetic lesions or "molecular signatures" as is the case with FLT3 mutations and overexpression of BAALC, ERG or MN1, or may have aberrations that predict better risk as is the case with isolated NPM1 or CEBPA mutations.” | 0.98 | hgnc_dict_v1 |
| gene | ERG | “Emerging evidence reveals that at the submicroscopic level, AML with normal cytogenetics may carry poor prognostic genetic lesions or "molecular signatures" as is the case with FLT3 mutations and overexpression of BAALC, ERG or MN1, or may have aberrations that predict better risk as is the case with isolated NPM1 or CEBPA mutations.” | 0.98 | hgnc_dict_v1 |
Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis.
PMID 19330068 | PMCID PMC2635624 | DOI 10.3390/ijms9112194 · International journal of molecular sciences · 2008 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | FLT3 | “Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis.” | 0.98 | hgnc_dict_v1 |
| phenotype | leukemia | “Detection of FLT3 oncogene mutations in acute myeloid leukemia using conformation sensitive gel electrophoresis.” | 0.98 | phenotype_alias_lexicon_v2 |
| population | Saudi Arabia | “Finally, this study reports, for the first time in Saudi Arabia, mutations in the human FLT3 gene in acute myeloid leukemia AML patients.” | 0.95 | saudi_context_rules_v1 |